Testing a new cancer treatment that targets TGFβ
Official title: Systematic Testing of a TGFβ Targeted Theranostic in Preclinical Cancer
Funded at University of California, San Francisco · NIH-11040515 · Data updated 2026-11-12
This study is exploring a new way to treat cancer by using a special therapy that targets a specific pathway in tumors, and it's designed for patients whose tumors show signs of this pathway, aiming to make treatment more effective for a wider variety of cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | December 16, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $676,567 |
| NIH project number | 1R01CA297601-01 |
| Project ID | NIH-11040515 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with breast, brain, or lung cancers that exhibit TGFβ activation.
✕Less likely to help
Patients with cancers that do not express TGFβ or those who are not eligible for radiopharmaceutical therapy may not benefit from this research.
What this research studies
This research investigates a novel approach to cancer treatment using radiopharmaceutical therapy (RPT) that targets the transforming growth factor beta (TGFβ) pathway. By utilizing advanced imaging techniques, patients will be selected based on the presence of TGFβ activation in their tumors, allowing for a more personalized treatment strategy. The study aims to combine a neutralizing antibody against TGFβ with therapeutic isotopes to enhance the effectiveness of cancer treatment. This approach could potentially expand the use of RPT to a broader range of cancers beyond those currently treated with this method.
Why it matters
Potential benefit: If successful, this research could provide a new, targeted treatment option for various types of cancer, improving patient outcomes.
How similar studies have gone: Previous research has shown promising results with targeted radiopharmaceutical therapies in other cancer types, suggesting potential for success with this novel approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Barcellos-Hoff, Mary Helen — University of California, San Francisco
- Study coordinator: Barcellos-Hoff, Mary Helen
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.